Hexiris Inc. (“Hexiris” or the “Company”), a leading R&D medtech company dedicated to developing innovative, accessible, and effective ophthalmic solutions for patients and community ophthalmologists, is pleased to announce the appointment of Paul Sowyrda and Steven Schiffman to its Board of Directors. Strategic Growth for Hexiris “We are thrilled to welcome Paul Sowyrda and…
We are thrilled to announce that Dr. Nir Shoham-Hazon, MD, the Co-Founder, CEO, and Scientific Director of Hexiris, has been honored with the prestigious 2024 ASCRS Educator Award. This recognition stands as a testament to Dr. Shoham-Hazon’s dedication, expertise, and outstanding contributions to the field of ophthalmology. The American Society of Cataract and Refractive Surgery…
DIEPPE, New Brunswick, April 02, – Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee. “We are proud that Dr. Harasymowycz has agreed…
DIEPPE, New Brunswick, Oct. 30, 2023 – Hexiris Inc. (“Hexiris” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris’s Scientific Committee. Dr. Ahmed is globally renowned for his skills and groundbreaking work in the diagnosis…
